Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna eyes international markets as growth driver, says Bank of America
08:58am, Wednesday, 08'th Apr 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results,...
You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500.
05:10am, Tuesday, 07'th Apr 2026
This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
06:01pm, Monday, 06'th Apr 2026
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, i
Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future
03:56am, Monday, 06'th Apr 2026
My previous recommendation of Moderna didn't work out so well, because COVID sales have declined over the last several years. Spikevax 2024 sales reached only $3.1B, and RSV sales were a major disappo
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
06:50pm, Thursday, 02'nd Apr 2026
In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 31'st Mar 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next
10:45am, Monday, 30'th Mar 2026
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
08:15am, Sunday, 29'th Mar 2026
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
06:51pm, Friday, 27'th Mar 2026
Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior day's close.
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
10:16am, Friday, 27'th Mar 2026
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
2 Healthcare Stocks That Could Soar Over the Next 5 Years
05:30pm, Thursday, 26'th Mar 2026
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
Moderna Stock is Soaring. Is It Too Late to Buy?
03:10pm, Wednesday, 25'th Mar 2026
Moderna's first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitted a flu vaccine candidate to regulators.
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
06:51pm, Friday, 20'th Mar 2026
In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
03:30pm, Thursday, 19'th Mar 2026
The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk.
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
12:49pm, Tuesday, 17'th Mar 2026
The first severe case of the virus has been detected in New York.
